OncoSec Secures Phesi ClinSite™ License to Select Clinical Trial Investigator Sites

EAST LYME, Conn.--(BUSINESS WIRE)-- Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced that OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) has purchased a multi-year ClinSite™ license to enable more accurate and precise planning for Phase 2 and 3 clinical trials of anticancer immunotherapies developed with OncoSec’s plasmid DNA delivery platform. ClinSite is a self-service, artificial intelligence (AI)-powered tool that allows biopharmaceutical companies to search for and select top-performing investigator sites for clinical trials in all therapeutic areas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200122005086/en/

“As a ClinSite licencee, OncoSec can utilize this novel tool to select the right investigator sites for their immune-oncology clinical trials across a range of tumor types,” said Gen Li, PhD, MBA, Phesi founder and president. “Many drug studies fail or are unnecessarily prolonged due to the lack of timely and precise data to inform trial protocols and investigator site selection. With our AI-driven predictive analytics and insights, Phesi’s tools generate accurate, real-time data, allowing companies such as OncoSec to accelerate their trial timelines and enhance their efficiency.”

“Access to Phesi’s innovative technology will be a boon to OncoSec’s clinical development programs, particularly our later-stage trials in advanced melanoma, head and neck cancer, and triple-negative breast cancer,” noted Kellie Malloy Foerter, chief clinical development officer at OncoSec. “Despite the relatively small patient populations affected by these malignancies, the array of unmet medical needs, combined with the sheer number of ongoing and planned clinical trials in these indications, presents a complex landscape for patients, investigators, and trial sponsors to negotiate. We are therefore excited to deploy ClinSite to optimize our clinical development planning processes, and are eager to see the results as Phesi’s ClinSite reporting capabilities evolve.”

Click here to request a live demonstration of the ClinSite platform.

About Phesi

Phesi provides comprehensive clinical development analytical products and services for biopharmaceutical companies around the world. The company’s integrated offerings cover the entire clinical development process — from development planning and indication assessment to protocol evaluation, site selection, and trial implementation management.

Phesi has the industry’s most comprehensive and dynamic clinical trials database and predictive analytics tools, consisting of 330,000 completed clinical trials, 604,000 completed research projects, 4.2 million physicians, and 1.8 million investigator records. ClinSite, a Software as a Service (SaaS) solution that incorporates natural language processing and machine learning, is an evolution of the technology Phesi patented in 2007 and fully automated in 2018.

For more information please visit Phesi.com. Click here to read our blog, and follow Phesi on LinkedIn and Twitter.

About OncoSec Medical Incorporated

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec has built a deep and diverse clinical pipeline utilizing its primary technology, TAVO™ (tavokinogene telseplasmid), as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.


Media Contact:
Reba Auslander
RAliance Communications


Source: Phesi

Back to news